News | April 10, 2021
Aurore to merge with Solara in an all-stock transaction
The merger is in line with Solara’s strategy of accelerating growth via appropriate inorganic actions
The merger is in line with Solara’s strategy of accelerating growth via appropriate inorganic actions
New regulation mandates stricter prescription monitoring, sales record maintenance, and enhanced compliance across the pharmaceutical supply chain
NGI will deliver full end-to-end workflows using both EpiFinder cNUC and EpiFinder GenomePro
The company’s shares of confidence were underlined by an upgraded 2026 outlook, with Merck now expecting annual net sales of up to €21.4 billion and EBITDA pre of as much as €6.1 billion
Pharma major to engage with institutional investors through group meetings in Mumbai and Singapore during May 2026
The CDMO segment saw a 22% decline in Q4 due to a strong base in the prior year
The biosimilars business generated Rs. 10,431 crore in FY26 revenue, up 16% year-on-year
U.S. business drives strong growth as Lupin reports 57% rise in Q4 U.S. sales and 43% increase in gross profit
With robust FY26 growth, plans AI-led diagnostics and genomic testing expansion
At the center of the deal is TERN-701, a drug recently granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration for adults with Philadelphia chromosome-positive chronic myeloid leukemia
Subscribe To Our Newsletter & Stay Updated
